We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals
IRWD

152 hedge funds and large institutions have $1.76B invested in Ironwood Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 26 increasing their positions, 96 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $8.76M | Put options by funds: $6.2M

6% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 32

3% less funds holding

Funds holding: 156 → 152 (-4)

16% less capital invested

Capital invested by funds: $2.09B → $1.76B (-$330M)

16.03% less ownership

Funds ownership: 119.69% → 103.66% (-16%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

73% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 96

Holders
152
Holders Change
-4
Holders Change %
-2.56%
% of All Funds
3.3%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
30
Increased
26
Reduced
96
Closed
32
Calls
$8.76M
Puts
$6.2M
Net Calls
+$2.56M
Net Calls Change
-$13.2M

Top Buyers

1
UBS AM
UBS AM
Illinois
+$19M
2
PCM
Peregrine Capital Management
Minnesota
+$13.8M
3
N
Nuveen
North Carolina
+$10.4M
4
BCPEMI
Bain Capital Public Equity Management II
Massachusetts
+$9.04M
5
SCM
Sarissa Capital Management
Connecticut
+$7.98M

Top Sellers

1
BM
Bridger Management
New York
-$56.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$45.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$40.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$25M
5
BlackRock
BlackRock
New York
-$18.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCPEMI
26
Bain Capital Public Equity Management II
Massachusetts
$8.82M +$9.04M +806,704 New
Goldman Sachs
27
Goldman Sachs
New York
$8.77M -$13.8M -1,234,362 -61%
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
$7.38M -$17.5M -1,563,750 -70%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$7.11M -$811K -72,374 -10%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$6.97M -$6.07M -541,759 -46%
Deutsche Bank
31
Deutsche Bank
Germany
$6.74M -$3.74M -334,166 -35%
Bank of America
32
Bank of America
North Carolina
$6.31M +$3.13M +279,310 +94%
OM
33
Opaleye Management
Massachusetts
$5.75M +$5.89M +525,400 New
Jacobs Levy Equity Management
34
Jacobs Levy Equity Management
New Jersey
$5.56M +$5.69M +508,143 New
HM
35
HealthCor Management
New York
$5.47M -$4.39M -392,154 -44%
1M
36
13D Management
New York
$5.36M +$5.48M +489,530 New
FI
37
Fosun International
China
$4.75M -$153K -13,691 -3%
UBS Group
38
UBS Group
Switzerland
$4.62M -$649K -57,904 -12%
PAM
39
Panagora Asset Management
Massachusetts
$4.29M +$977K +87,225 +29%
CEP
40
Chicago Equity Partners
Illinois
$4.22M -$876K -78,191 -17%
Millennium Management
41
Millennium Management
New York
$4.17M -$7.34M -654,994 -63%
PI
42
Putnam Investments
Massachusetts
$3.78M +$3.87M +345,600 New
BCB
43
Brian C. Broderick
$3.6M -$716K -63,871 -16%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$3.51M -$697K -62,246 -16%
American Century Companies
45
American Century Companies
Missouri
$3.17M +$546K +48,720 +20%
Swiss National Bank
46
Swiss National Bank
Switzerland
$3.15M -$192K -17,128 -6%
Wells Fargo
47
Wells Fargo
California
$3.02M -$903K -80,636 -23%
Rafferty Asset Management
48
Rafferty Asset Management
New York
$2.81M +$141K +12,568 +5%
AllianceBernstein
49
AllianceBernstein
Tennessee
$2.61M -$32.5K -2,897 -1%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$2.59M -$230K -20,566 -8%
1
2
3 4 5

IRWD Hedge Fund Activity: Q2 2019 in Review

152 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2019, worth a combined $1.76B — down 16% from $2.09B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of IRWD and 30 opened new positions — a net loss of 2 holders — while 96 trimmed existing stakes and 26 added.

The largest buyer was UBS AM, adding an estimated $19M. The largest seller was Bridger Management, exiting entirely with an estimated $56.6M sold.

  • 152 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2019, down from 156 in Q1 2019.
  • Funds reported $1.76B of Ironwood Pharmaceuticals stock for Q2 2019, down 16% quarter-over-quarter.
  • 30 funds opened new Ironwood Pharmaceuticals positions in Q2 2019 and 32 closed out, a net change of -2 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q2 2019 was UBS AM, an estimated $19M added.
  • The largest Ironwood Pharmaceuticals seller in Q2 2019 was Bridger Management, an estimated $56.6M sold.

Based on aggregated 13F filings for Q2 2019.